

# **CURRICULUM VITAE**

## **FABIO MANGIACAPRA, MD, PhD**

### **PERSONAL INFORMATION**

**Name:** Fabio Mangiacapra

**Date and Place of Birth:** April 8, 1981 - Naples, Italy

**Nationality:** Italian

**Marital Status:** Married

**Email address:** [f.mangiacapra@unicampus.it](mailto:f.mangiacapra@unicampus.it)  
fabio.mangiacapra@gmail.com

### **CURRENT APPOINTMENT**

Clinical and Interventional Cardiologist, Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Italy

### **CERTIFICATIONS / LICENSURE**

Diplomate, Italian Board of Cardiovascular Disease (Campus Bio-Medico University, Rome, Italy 2009)

Italian unrestricted license to practice Medicine (Campus Bio-Medico University, Rome, Italy 2006)

## **EDUCATION**

Eindhoven University of Technology, Eindhoven, The Netherlands, 2010-2012, PhD in Biomedical Engineering.

Campus Bio-Medico University of Rome Medical School, Rome, Italy, 1999-2005, MD degree, Graduated "summa cum laude" with honourable mention.

Liceo Classico "Domenico Cirillo", Aversa, Italy 1994-1999, Graduated with honors (100/100).

## **POSTDOCTORAL TRAINING**

August 2008 - September 2011      Fellow in Interventional Cardiology  
Cardiovascular Centre Aalst  
Aalst, Belgium

October 2005 - October 2009      Fellow in Cardiology  
Campus Bio-Medico University  
Rome, Italy

## **SCIENTIFIC SOCIETIES**

European Society of Cardiology (ESC) - Fellow

Italian Society of Cardiovascular Research (SIRC) – Board Member

European Association of Percutaneous Cardiovascular Intervention (EAPCI) - Member

Italian Society of Cardiology (SIC) - Member

Italian Society of Invasive Cardiology (GISE) - Member

## **COURSES/MEETINGS PARTICIPATED AS FACULTY**

Faculty, EuroPCR, official congress of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Paris, France, May 25<sup>th</sup>-28<sup>th</sup>, 2010

Faculty, 11th Aalst-Eindhoven Meeting on Coronary Physiology, Brussels, Belgium, June 10<sup>th</sup>-11<sup>th</sup>, 2010

Faculty, EuroPCR, official congress of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Paris, France, May 17<sup>th</sup>-20<sup>th</sup>, 2011

Faculty, Congress of the Italian Society of Interventional Cardiology (GISE), Genoa, Italy, October 3<sup>rd</sup>-5<sup>th</sup>, 2012

Faculty, Congress of the Italian Society of Cardiology, Rome, Italy, December 15<sup>th</sup>-17<sup>th</sup>, 2012

Faculty, American College of Cardiology Scientific Sessions, San Francisco, California, March 9<sup>th</sup>-11<sup>th</sup>, 2013

Faculty, Congress of the Italian Society of Interventional Cardiology (GISE), Genoa, Italy, October 9<sup>th</sup>-11<sup>th</sup>, 2013

Faculty, Congress of the Italian Society of Interventional Cardiology (GISE), Genoa, Italy, October 27<sup>th</sup>-30<sup>th</sup>, 2015

Faculty, Congress of the Italian Society of Cardiovascular Research (SIRC), Imola, Italy, November 26<sup>th</sup>-28<sup>th</sup>, 2015

## **AWARDS / ACADEMIC ACHIEVEMENTS**

Finalist for the **Young Investigator Award** at the Italian Society of Cardiology Congress 2009 for the abstract *"Diabetes Mellitus is Associated With Inadequate Platelet Inhibition After Clopidogrel and With Poorer Peri-procedural Outcome in Patients Undergoing Percutaneous Coronary Intervention"*

Winner of the **Best Abstract Award** at the Italian Society of Interventional Cardiology (GISE) Congress 2009 for the abstract *"High Residual Platelet Reactivity After Clopidogrel, Extent of Coronary Atherosclerosis and Peri-Procedural Myocardial Infarction in Patients With Stable Angina Undergoing PCI"*

Recipient of the **European Association of Percutaneous Coronary Intervention (EAPCI) Interventional Cardiology Research Grant 2009** (24.000€)

Winner of the **Best Cardiology Board Graduation Thesis Award** at the Italian Society of Cardiology Congress 2010 for the thesis *"Role Of Vascular Atherosclerosis in Platelet Response To Clopidogrel In Patients Undergoing Percutaneous Coronary Intervention"*

Winner of the **Young Investigator Award** at the Italian Society of Cardiology Congress 2011 for the abstract *"Validating ARMYDA-PRO/BLEEDS: a Therapeutic Window in Platelet Reactivity for Patients Undergoing Elective Percutaneous Coronary Intervention"*

Winner of the **2011 Young Author Achievement Award for JACC Cardiovascular Interventions** for the paper *"A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study"*

Winner of the **Young Investigator Award** at the European Society of Cardiology Congress 2012 for the abstract *"Intracoronary enalaprilat improves microvascular function and protects myocardium in patients undergoing PCI: a randomized double-blind controlled study"*

## **EDITORIAL CONSULTANT (MANUSCRIPT REVIEWER)**

Journal of Cardiovascular Translational Research (Editorial Board Member)

Journal of the American College of Cardiology

European Heart Journal

JACC Cardiovascular Interventions

American Journal of Cardiology

Catheterization and Cardiovascular Interventions

EuroIntervention

International Journal of Cardiovascular Imaging

Journal of Cardiovascular Medicine

American Journal of Cardiovascular Drugs

Plos One

Cardiology

Platelets

CardioRenal Medicine

---

## **ORIGINAL ARTICLES**

1. Patti G, Nusca A, **Mangiaccapra F**, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. *J Am Coll Cardiol.* 2008;52:1128-1133. IF: 11.438
2. Muller O, Hamilos M, Bartunek J, Ulrichs H, **Mangiaccapra F**, Holz JB, Ntalianis A, Trana C, Dierickx K, Vercruysse K, De Bruyne B, Wijns W, Barbato E. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. *Am J Cardiol.* 2010;105:333-338. IF 3.681
3. **Mangiaccapra F**, De Bruyne B, Muller O, Trana C, Ntalianis A, Bartunek J, Heyndrickx G, Di Sciascio G, Wijns W, Barbato E. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. *JACC Cardiovasc Interv.* 2010;3:35-40. IF: 5.862
4. **Mangiaccapra F**, Barbato E, Patti G, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Wijns W, Di Sciascio G. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. *JACC Cardiovasc Interv.* 2010;3:318-323. IF: 5.862
5. Di Sciascio G, Patti G, Pasceri V, Colonna G, **Mangiaccapra F**, Montinaro A. Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. *Eur Heart J.* 2010;31:1337-1343. IF: 10.052
6. **Mangiaccapra F**, Barbato E. Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. *Biomark Med.* 2010;4:421-434. IF: 1.247
7. **Mangiaccapra F**, Wijns W, De Luca G, Muller O, Trana C, Ntalianis A, Heyndrickx G, Vanderheyden M, Bartunek J, De Bruyne B, Barbato E. Thrombus aspiration in primary percutaneous coronary intervention in high-risk patients with ST-elevation myocardial infarction: a real-world registry. *Catheter Cardiovasc Interv.* 2010;76:70-76. IF: 2.398
8. **Mangiaccapra F**, Muller O, Ntalianis A, Trana C, Heyndrickx GR, Bartunek J, Vanderheyden M, Wijns W, De Bruyne B, Barbato E. Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. *Am J Cardiol.* 2010;106:1208-1211. IF: 3.681
9. Ntalianis A, Trana C, Muller O, **Mangiaccapra F**, Peace A, De Backer C, De Block L, Wyffels E, Bartunek J, Vanderheyden M, Heyse A, Van Durme F, Van Driessche L, De Jans J, Heyndrickx GR, Wijns W, Barbato E, De Bruyne B.

Effective radiation dose, time, and contrast medium to measure fractional flow reserve. *JACC Cardiovasc Interv.* 2010;3:821-827. IF: 5.862

10. **Mangiacapra F**, Patti G, Peace A, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Muller O, Barbato E, Di Sciascio G. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. *Am J Cardiol.* 2010;106:619-623. IF: 3.681
11. **Mangiacapra F**, Trana C, Sarno G, Davidavicius G, Protasiewicz M, Muller O, Ntalianis A, Misonis N, Van Vlem B, Heyndrickx GR, De Bruyne B. Translesional pressure gradients to predict blood pressure response after renal artery stenting in patients with renovascular hypertension. *Circ Cardiovasc Interv.* 2010;3:537-542. IF: 4.364
12. Ntalianis A, Sels JW, Davidavicius G, Tanaka N, Muller O, Trana C, Barbato E, Hamilos M, **Mangiacapra F**, Heyndrickx GR, Wijns W, Pijls NH, De Bruyne B. Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. *JACC Cardiovasc Interv.* 2010;3:1274-1281. IF: 5.862
13. **Mangiacapra F**, Peace AJ, Wijns W, Barbato E. Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel. *J Thromb Thrombolys.* 2011;32:54-8. IF: 1.476
14. Mylotte D, Peace AJ, Tedesco AT, **Mangiacapra F**, Dicker P, Kenny D, Foley DP. Clopidogrel discontinuation and platelet reactivity following coronary stenting. *J Thromb Haemost.* 2011;9:24-32. IF: 5.731
15. **Mangiacapra F**, Di Serafino L, Barbato E. The role of fractional flow reserve to guide stent implantation. *Minerva Cardioangiol.* 2011;59:39-48.
16. Hamilos M, Muller O, Ntalianis A, Trana C, Bartunek J, Sarno G, **Mangiacapra F**, Dierickx K, Meeus P, Cuisset T, De Bruyne B, Wijns W, Barbato E. Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. *J Thromb Thrombolysis.* 2011;32:64-71. IF: 1.476
17. **Mangiacapra F**, Barbato E. From SYNTAX to FAME, a paradigm shift in revascularization strategies: the key role of fractional flow reserve in guiding myocardial revascularization. *J Cardiovasc Med.* 2011;8:538-42. IF: 1.510
18. Nusca A, Patti G, Marino F, **Mangiacapra F**, D'Ambrosio A, Di Sciascio G. Prognostic role of preprocedural glucose levels on short- and long-term outcome in patients undergoing percutaneous coronary revascularization. *Catheter Cardiovasc Interv.* 2012;80:377-84. IF: 2.514
19. Muller O, Delrue L, Hamilos M, Vercauteren S, Ntalianis A, Trana C, **Mangiacapra F**, Dierickx K, De Bruyne B, Wijns W, Behfar A, Barbato E, Terzic A, Vanderheyden M, Bartunek J. Transcriptional fingerprint of human whole blood at the site of coronary occlusion in acute myocardial infarction. *EuroIntervention.* 2011;4:458-66. IF: 3.285

20. **Mangiaccapra F**, De Bruyne B, Wijns W, Bartunek J. Optimizing Revascularization Strategies in Coronary Artery Disease for Optimal Benefit to Patients. *Clin Pharmacol Ther.* 2011;90:630-3. IF: 6.043
21. Nam CW, **Mangiaccapra F**, Entjes R, Chung IS, Sels JW, Tonino PA, De Bruyne B, Pijls NH, Fearon WF; FAME Study Investigators. Functional SYNTAX Score for Risk Assessment in Multivessel Coronary Artery Disease. *J Am Coll Cardiol.* 2011;58:1211-8. IF: 14.156
22. Patti G, Bárczi G, Orlic D, **Mangiaccapra F**, Colonna G, Pasceri V, Barbato E, Merkely B, Edes I, Ostojic M, Wijns W, Di Sciascio G. Outcome Comparison of 600- and 300-mg Loading Doses of Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Results From the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) Randomized Study. *J Am Coll Cardiol.* 2011;58:1592-9. IF: 14.156
23. Muller O, **Mangiaccapra F**, Ntalianis A, Verhamme KM, Trana C, Hamilos M, Bartunek J, Vanderheyden M, Wyffels E, Heyndrickx GR, van Rooij FJ, Witteman JC, Hofman A, Wijns W, Barbato E, De Bruyne B. Long-term follow-up after fractional flow reserve-guided treatment strategy in patients with an isolated proximal left anterior descending coronary artery stenosis. *JACC Cardiovasc Interv.* 2011;4:1175-82. IF: 6.800
24. Puymirat E, **Mangiaccapra F**, Peace A, Sharif F, Conte M, Bartunek J, Vanderheyden M, Wijns W, de Bruyne B, Barbato E. Long-term clinical outcome in patients with small vessel disease treated with drug-eluting versus bare-metal stenting. *Am Heart J.* 2011;162:907-13. IF: 4.651
25. Barbato E, Bartunek J, Marchitti S, **Mangiaccapra F**, Stanzione R, Delrue L, Cotugno M, Di Castro S, De Bruyne B, Wijns W, Volpe M, Rubattu S. NT-proANP circulating level is a prognostic marker in stable ischemic heart disease. *Int J Cardiol.* 2012;155:311-2. IF: 5.509
26. **Mangiaccapra F**, Heyndrickx GR, Puymirat E, Peace AJ, Wijns W, De Bruyne B, Barbato E. Comparison of drug-eluting versus bare-metal stents after rotational atherectomy for the treatment of calcified coronary lesions. *Int J Cardiol.* 2012;154:373-6. IF: 5.509
27. Fournier S, Eeckhout E, **Mangiaccapra F**, Trana C, Lauriers N, Beggah AT, Monney P, Cook S, Bardy D, Vogt P, Muller O. Circadian variations of ischemic burden among patients with myocardial infarction undergoing primary percutaneous coronary intervention. *Am Heart J.* 2012;163:208-13. IF: 4.497
28. Puymirat E, Peace A, **Mangiaccapra F**, Conte M, Ntarladimas Y, Bartunek J, Vanderheyden M, Wijns W, De Bruyne B, Barbato E. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary revascularization in patients with small-vessel disease. *Circ Cardiovasc Interv.* 2012;5:62-8. IF: 6.543

29. **Mangiacapra F**, De Bruyne B, Peace AJ, Melikian N, Wijns W, Barbato E. High cholesterol levels are associated with coronary microvascular dysfunction. *J Cardiovasc Med*. 2012;13:439-42. IF: 2.657
30. **Mangiacapra F**, Patti G, Barbato E, Peace AJ, Ricottini E, Vizzi V, Gatto L, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. *JACC Cardiovasc Interv*. 2012;5:281-9. IF: 6.552
31. Barbato E, Bartunek J, **Mangiacapra F**, Sciarretta S, Stanzione R, Delrue L, Cotugno M, Marchitti S, Iaccarino G, Sirico G, Di Castro S, Evangelista A, Lambrechts D, Sinnaeve P, De Bruyne B, Van De Werf F, Janssens S, Fox KA, Wijns W, Volpe M, Rubattu S. Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. *J Am Coll Cardiol*. 2012;59:1763-70. IF: 14.086
32. Di Sciascio G, **Mangiacapra F**. Platelet Reactivity and Percutaneous Coronary Intervention: Another Clue in the Quest for the Holy Grail of Tailored Antithrombotic Therapy? *J Am Coll Cardiol*. 2012;60:378-80. IF: 14.086
33. **Mangiacapra F**, Patti G, Barbato E, Orlic D, Peace AJ, D'Ambrosio A, Ostojic M, Wijns W, Di Sciascio G. Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) Study. *Int J Cardiol*. 2012;160:213-4. IF: 5.509
34. **Mangiacapra F**, Bartunek J, Bijmens N, Peace AJ, Dierickx K, Bailleul E, Di Serafino L, Pyxaras SA, Fraeyman A, Meeus P, Rutten M, De Bruyne B, Wijns W, VAN de Vosse F, Barbato E. Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. *J Thromb Haemost*. 2012;10:2452-61. IF: 6.081
35. Muller O, Pyxaras SA, Trana C, **Mangiacapra F**, Barbato E, Wijns W, Taylor CA, De Bruyne B. Pressure-diameter relationship in human coronary arteries. *Circ Cardiovasc Interv*. 2012;5:791-6. IF: 6.543
36. Muller O, Bartunek J, Hamilos M, Berza CT, **Mangiacapra F**, Ntalianis A, Vercruysse K, Duby C, Wijns W, De Bruyne B, Heyndrickx GR, Vanderheyden M, Holz JB, Barbato E. von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina. *J Cardiovasc Transl Res*. 2013;6:364-70. IF: 2.691
37. Pyxaras SA, Sinagra G, **Mangiacapra F**, Perkan A, Di Serafino L, Vitrella G, Rakar S, De Vroey F, Santangelo S, Salvi A, Toth G, Bartunek J, De Bruyne B, Wijns W, Barbato E. Contrast-Induced Nephropathy in Patients Undergoing Primary Percutaneous Coronary Intervention Without Acute Left Ventricular Ejection Fraction Impairment. *Am J Cardiol*. 2013;111:684-8. IF: 3.425



38. **Mangiacapra F**, Barbato E. Clinical Implications of Platelet-Vessel Interaction. *J Cardiovasc Transl Res.* 2013;6:310-5. IF: 2.691
39. **Mangiacapra F**, Peace AJ, Di Serafino L, Pyxaras SA, Bartunek J, Wyffels E, Heyndrickx GR, Wijns W, De Bruyne B, Barbato E. Intracoronary Enalaprilat to Reduce Microvascular Damage During Percutaneous Coronary Intervention (ProMicro) Study. *J Am Coll Cardiol.* 2013;61:615-21. IF: 15.343
40. Pyxaras SA, **Mangiacapra F**, Verhamme K, Di Serafino L, De Vroey F, Toth G, Perkan A, Salvi A, Bartunek J, De Bruyne B, Wijns W, Sinagra G, Barbato E. Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention. *Catheter Cardiovasc Interv.* 2013 Oct 1;82:604-11 IF: 2.396
41. Patti G, **Mangiacapra F**, Ricottini E, Cannatà A, Cavallari I, Vizzi V, D'Ambrosio A, Dicuonzo G, Di Sciascio G. Correlation of Platelet Reactivity and C-Reactive Protein Levels to Occurrence of Peri-Procedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the ARMYDA-CRP Study). *Am J Cardiol.* 2013;111:1739-44. IF: 3.425
42. Di Serafino L, Pyxaras SA, **Mangiacapra F**, Dierickx K, Toth G, Bartunek J, De Bruyne B, Van Mieghem C, Wijns W, Barbato E. Influence of transradial versus transfemoral diagnostic heart catheterisation on peripheral vascular endothelial function. *EuroIntervention.* 2013;8:1252-8. IF: 3.758
43. Patti G, Pasceri V, **Mangiacapra F**, Colonna G, Vizzi V, Ricottini E, Montinaro A, D'Ambrosio A, Wijns W, Barbato E, Di Sciascio G; ARMYDA-8 RELOAD-ACS Investigators. Efficacy of Clopidogrel Reloading in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention During Chronic Clopidogrel Therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] Trial). *Am J Cardiol.* 2013;112:162-8. IF: 3.425
44. Muller O, Ntalianis A, Wijns W, Delrue L, Dierickx K, Auer R, Rodondi N, **Mangiacapra F**, Trana C, Hamilos M, Valentin E, De Bruyne B, Barbato E, Bartunek J. Association of Biomarkers of Lipid Modification with Functional and Morphological Indices of Coronary Stenosis Severity in Stable Coronary Artery Disease. *J Cardiovasc Transl Res.* 2013;6:536-44. IF: 2.691
45. Di Serafino L, De Bruyne B, **Mangiacapra F**, Bartunek J, Agostoni P, Vanderheyden M, Scognamiglio G, Heyndrickx GR, Wijns W, Barbato E. Long-term clinical outcome after fractional flow reserve- versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts. *Am Heart J.* 2013;166:110-8. IF: 4.555
46. **Mangiacapra F**, Peace A, Barbato E, Patti G, Gatto L, Ricottini E, De Bruyne B, Di Sciascio G, Wijns W. Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. *Platelets.* 2014;25:348-56. IF: 2.982
47. Fournier S, Puricel S, Morawiec B, Eeckhout E, **Mangiacapra F**, Trana C, Taponnier M, Iglesias JF, Michiels V, Stauffer JC, Beggah A, Monney P, Gobet S, Vogt P, Cook S, Muller O. Relationship between time of day and

periprocedural myocardial infarction after elective angioplasty. *Chronobiol Int.* 2014;31:206-13. IF: 3.343

48. Puymirat E, **Mangiacapra F**, Peace A, Ntarladimas Y, Conte M, Bartunek J, Vanderheyden M, Wijns W, de Bruyne B, Barbato E. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease. *Arch Cardiovasc Dis.* 2013;106:554-61. IF: 1.662
49. Pyxaras SA, Tu S, Barbato E, Barbati G, Di Serafino L, De Vroey F, Toth G, **Mangiacapra F**, Sinagra G, De Bruyne B, Reiber JH, Wijns W. Quantitative angiography and optical coherence tomography for the functional assessment of nonobstructive coronary stenoses: comparison with fractional flow reserve. *Am Heart J.* 2013;166:1010-1018. IF: 4.555
50. Pyxaras SA, **Mangiacapra F**, Wijns W, Di Serafino L, De Vroey F, Toth G, Sinagra G, De Bruyne B, Heyndrickx GR, Barbato E. ACEF and clinical SYNTAX score in the risk stratification of patients with heavily calcified coronary stenosis undergoing rotational atherectomy with stent implantation. *Catheter Cardiovasc Interv.* 2014;83:1067-73. IF: 2.107
51. **Mangiacapra F**, Cavallari I, Barbato E, Ricottini E, Patti G, Vizzi V, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G. Impact of Chronic Kidney Disease on Platelet Reactivity and Outcomes of Patients Receiving Clopidogrel and Undergoing Percutaneous Coronary Intervention. *Am J Cardiol.* 2014 1;113:1124-9. IF: 3.276
52. Toth G, Hamilos M, Pyxaras S, **Mangiacapra F**, Nelis O, De Vroey F, Di Serafino L, Muller O, Van Mieghem C, Wyffels E, Heyndrickx GR, Bartunek J, Vanderheyden M, Barbato E, Wijns W, De Bruyne B. Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses. *Eur Heart J.* 2014 21;35:2831-8. IF: 15.203
53. Peace AJ, **Mangiacapra F**, Bailleul E, Delrue L, Dierickx K, Conte M, Puymirat E, Fraeymans AL, Meeus P, Bartunek J, Volpe M, Barbato E.  $\alpha$ 2A-Adrenergic Receptor Polymorphism Potentiates Platelet Reactivity in Patients With Stable Coronary Artery Disease Carrying the Cytochrome P450 2C19\*2 Genetic Variant. *Arterioscler Thromb Vasc Biol.* 2014;34:1314-9. IF: 6.368
54. Patti G, De Caterina R, Abbate R, Andreotti F, Biasucci LM, Calabrò P, Cioni G, Davì G, Di Sciascio G, Golia E, Golino P, Malatesta G, **Mangiacapra F**, Marcucci R, Nusca A, Parato VM, Pengo V, Prisco D, Pulcinelli F, Renda G, Ricottini E, Ruggieri B, Santilli F, Sofi F, Zimarino M; on behalf of the Working Group on Thrombosis of the Italian Society of Cardiology. Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper. *Eur Heart J.* 2014;35:2213-2223. IF: 15.203
55. Tocchetti CG, Molinaro M, Angelone T, Lionetti V, Madonna R, **Mangiacapra F**, Moccia F, Penna C, Sartiani L, Quaini F, Pagliaro P. Nitroso-Redox Balance and Modulation of Basal Myocardial Function: an Update from the Italian Society of Cardiovascular Research (SIRC). *Curr Drug Targets.* 2015;16:895-903.

56. **Mangiapra F**, Ricottini E, Di Gioia G, Peace A, Patti G, De Bruyne B, Wijns W, Barbato E, Di Sciascio G. Comparison Among Patients  $\geq 75$  Years Having Percutaneous Coronary Angioplasty Using Drug-Eluting Stents Versus Bare Metal Stents. *Am J Cardiol.* 2015;115:1179-84.
57. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, Ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, **Mangiapra F**, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. *Eur Heart J.* 2015;36:1762-71.
58. **Mangiapra F**, Cavallari I, Ricottini E, Pellicano M, Barbato E, Di Sciascio G. High platelet reactivity and periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: A significant association beyond definitions. *Int J Cardiol.* 2015;190:124-125.
59. **Mangiapra F**, Ricottini E, Barbato E, Demartini C, Peace A, Patti G, Vizzi V, De Bruyne B, Wijns W, Di Sciascio G. Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding After Percutaneous Coronary Intervention via the Femoral Approach Development and Validation of a New Bleeding Risk Score. *Circ Cardiovasc Interv.* 2015;8(5).
60. Nusca A, Lauria Pantano A, Melfi R, Proscia C, Maddaloni E, Contuzzi R, **Mangiapra F**, Palermo A, Manfrini S, Pozzilli P, Di Sciascio G. Glycemic Variability Assessed by Continuous Glucose Monitoring and Short-Term Outcome in Diabetic Patients Undergoing Percutaneous Coronary Intervention: An Observational Pilot Study. *J Diabetes Res.* 2015;2015:250201.
61. Miglionico M, **Mangiapra F**, Nusca A, Scordino D, Gallo P, Campanale M, Melfi R, Di Sciascio G. Efficacy and Safety of Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis in High-Risk Patients. *Am J Cardiol.* 2015;116:1690-4.
62. **Mangiapra F**, Di Gioia G, Pellicano M, Di Serafino L, Bressi E, Peace AJ, Bartunek J, Wijns W, De Bruyne B, Barbato E. Effects Of Prasugrel Versus Clopidogrel On Coronary Microvascular Function In Patients Undergoing Elective Percutaneous Coronary Intervention: Results Of The PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-2 Randomized Study. *J Am Coll Cardiol.* *In press*

## **ARTICLES AS INVESTIGATOR**

1. Di Sciascio G, Patti G, Pasceri V, Gatto L, Colonna G, Montinaro A; ARMYDA-5 PRELOAD Investigators. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet

therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. *J Am Coll Cardiol.* 2010;56:550-7.

2. Valgimigli M; MATRIX investigators. Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program. *Am Heart J.*;168:838-45.
3. Valgimigli M, Gagnor A, Calabrò P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbühler M, Vranckx P, Jüni P; MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. *Lancet.* 2015;385:2465-76.
4. Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van 't Hof A, Boccuzzi G, Omerovic E, Sabaté M, Heg D, Jüni P, Vranckx P; MATRIX Investigators. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. *N Engl J Med.* 2015;373:997-1009.

## **RESEARCH CORRESPONDANCE**

- **Mangiacapra F**, Barbato E. Letter by Mangiacapra and Barbato regarding article, "Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease". *Circ Cardiovasc Interv.* 2013;6:e65.

## **BOOK CHAPTERS**

- Dual antiplatelet therapy prior to percutaneous coronary intervention. Authors: **Fabio Mangiacapra**, Annunziata Nusca, Rosetta Melfi, Germano Di Sciascio. *Antiplatelet Therapy*, 1st edition. Editor: Ron Waksman. Wiley Online Library.

## **PUBLISHED ABSTRACTS**

### **International Cardiology Meetings:**

1. **Mangiacapra F**, Patti G, Gatto L, Nusca A, Vizzi V, Ricottini E, D'Ambrosio A, Wijns W, Barbato E, Di Sciascio G. Platelet Response to Clopidogrel Assessed by a Point-of-Care Assay Predicts Myocardial Necrosis After Elective Percutaneous Coronary Intervention. *Circulation* 120: S933-d-934S -d.

2. **Mangiacapra F**, Patti G, Gatto L, Nusca A, Vizzi V, Ricottini E, D'Ambrosio A, Di Sciascio G. Diabetes Mellitus is Associated With Inadequate Platelet Inhibition After Clopidogrel and With Poorer Peri-procedural Outcome in Patients Undergoing Percutaneous Coronary Intervention. *Circulation* 120: S933-b.
3. Muller O, Ntalianis A, Trana C, **Mangiacapra F**, Barbato E, Heyndrickx G, Vanderheyden M, Bartunek J, Wijns W, De Bruyne B. Vasodilation of Coronary Artery After Stenting: Choosing the Correct Stent Size in Tight Stenosis. *Circulation* 120: S927-a.
4. Ntalianis A, Trana C, Muller O, Barbato E, Vanderheyden M, **Mangiacapra F**, De Backer C, Heyndrickx GR, Wijns W, De Bruyne B. Radiation, Contrast Medium and Time Needed for Fractional Flow Reserve Assessment After a Left Heart Catheterization. *Circulation* 120: S927.
5. **Mangiacapra F**, Muller O, Trana C, Ntalianis A, Bartunek J, Heyndrickx GR, De Bruyne B, Wijns W, Barbato E. Adjunctive Thrombus Aspiration in Primary Percutaneous Coronary Intervention in Real-world Patients With ST-elevation Myocardial Infarction. *Circulation* 120: S960-a.
6. **Mangiacapra F**, Muller O, Trana C, Ntalianis A, Heyndrickx GR, Bartunek J, De Bruyne B, Wijns W, Di Sciascio G, Barbato E. High Platelet Reactivity After Clopidogrel Correlates With the Extent of Coronary Atherosclerosis and Predicts Peri-procedural Outcome in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention. *Circulation* 120: S937-a
7. Gatto L, Patti G, Chello M, Ricottini E, Colonna D, Covino E, Miglionico M, **Mangiacapra F**, Nusca A, Di Sciascio G. Procedural myocardial protection by short-term atorvastatin load is related to lower levels of adhesion molecules after percutaneous coronary intervention in patients with acute coronary syndromes. results from the armyda-acs cams (atorvastatin for reduction of myocardial damage during angioplasty-cell adhesion molecules) substudy. *J Am Coll Cardiol* 55: A188.E1760.
8. Nusca A, Marino F, Patti G, **Mangiacapra F**, Gatto L, D'Ambrosio A, Melfi R, Miglionico M, Di Sciascio G. Hypoglycemia is associated with an increased incidence of peri-procedural myocardial damage in non-diabetic patients undergoing coronary angioplasty. *J Am Coll Cardiol* 55: A209.E1977.
9. Nusca A, Patti G, Marino F, **Mangiacapra F**, Gatto L, Miglionico M, Melfi R, D'Ambrosio A, Di Sciascio G. Both hypoglycemia and hyperglycemia are associated with increased incidence of in-stent restenosis in patients undergoing elective coronary angioplasty. *J Am Coll Cardiol* 55: A195.E1826.
10. Ntalianis A, Balliauw C, Trana C, **Mangiacapra F**, Vanderheyden M, Bartunek J, Barbato E, Wijns W, Vanhoenacker P, De Bruyne B. Early and late left ventricular remodeling after acute myocardial infarction: predictive value of microcirculatory resistance of the culprit and non-culprit territories. *Eur Heart J* 2010;31 (suppl 1).
11. Barbato E, **Mangiacapra F**, Delrue L, Sciarretta S, Stanzione R, Bartunek J, Morriello A, De Giusti M, Volpe M, Rubattu S. The C-664G promoter variant of A-type natriuretic peptide gene is protective for coronary atherosclerosis. *Eur*

Heart J 2010;31 (suppl 1).

12. Ntalianis A, Sells JW, Davidavicius G, Tanaka N, Trana C, **Mangiaccapra F**, Hamilos M, Wijns W, Pijls NHJ, De Bruyne B. Predictors of the reproducibility of fractional flow reserve for the functional evaluation of non-culprit coronary artery stenoses in patients with acute coronary syndromes. *Eur Heart J* 2010;31 (suppl 1).
13. Ntalianis A, Bodea O, Delrue L, Dierickx K, Heyndrickx B, Muller O, **Mangiaccapra F**, Barbato E, Vanderheyden M, Bartunek J. Impact of renin-angiotensin system genetic polymorphisms on short- and long-term survival rates in patients with severe pressure overload cardiomyopathy. *Eur Heart J* 2010;31 (suppl 1).
14. Muller O, **Mangiaccapra F**, Ntalianis A, Trana C, Hamilos M, Bartunek J, Vanderheyden M, Wijns W, Barbato E, De Bruyne B. Long term follow-up after fractional flowreserve-guided treatment strategy of isolated proximal left anterior descending coronary artery stenoses. *Eur Heart J* 2010;31 (suppl 1).
15. Ntalianis A, Trana C, Muller O, **Mangiaccapra F**, Peace A, Hamilos M, Cuisset T, Conte M, Bartunek J, Wijns W. Safety and efficacy of reloading doses of clopidogrel and aspirin before elective PCI to optimize periprocedural outcome in elderly. *Eur Heart J* 2010;31 (suppl 1).
16. Ntalianis A, Puymirat E, Conte M, Peace A, **Mangiaccapra F**, Muller O, Trana C, Heyndrickx GR, Barbato E, Wijns W. Ergonovine-induced coronary artery spasm and long-term survival in patients with chest pain and non-significant coronary artery stenosis. *Eur Heart J* 2010;31 (suppl 1).
17. **Mangiaccapra F**, Trana C, Sarno G, Davidavicius G, Protasiewicz M, Ntalianis A, Muller O, Wyffels E, Heyndrickx GR, De Bruyne B. Do resting and/or hyperaemic translesional pressure gradients predict clinical outcome after renal stenting angioplasty? *Eur Heart J* 2010;31 (suppl 1).
18. Ntalianis A, De Bruyne B, Trana C, **Mangiaccapra F**, Muller O, Peace A, Hamilos M, Bartunek J, Wijns J, Barbato E. Fractional Flow Reserve versus Angiography to Assess Progression of Atherosclerosis. *Circulation* 2010; 122: A19113.
19. Ntalianis A, Muller O, Trana C, **Mangiaccapra F**, Barbato E, Dierickx K, Delrue L, Van Vlem B, Bartunek J, Vanderheyden M. Multi-Biomarker Approach for the Prediction of Acute Kidney Injury and Short-Term Clinical Outcome in Patients Undergoing Coronary Angiography. *Circulation* 2010; 122: A18402.
20. Peace AJ, **Mangiaccapra F**, Bailleul E, Delrue L, Conte M, Puymirat E, Fraeyman A, Meeus P, Bartunek J, Barbato E. Platelet Aggregation in Stable Angina Patients Treated With Aspirin and Clopidogrel is Modulated by 6.3 / 6.7 Kb Polymorphism of the Platelet Alpha2a-Adrenergic Receptor. *Circulation* 2010; 122: A18363.
21. Ntalianis A, Etienne E, Conte M, Peace A, **Mangiaccapra F**, Muller O, Trana C, Heyndrickx GR, Barbato E, Wijns W. Coronary Artery Spasm and Prognosis in Patients on Optimal Chronic Antispasmodic Therapy. *Circulation* 2010; 122: A20989.

22. Ntalianis A, Trana C, Muller O, **Mangiaccapra F**, Peace A, Hamilos M, Cuisset T, Conte M, Bartunek J, Barbato E, Wijns W. Is Age an Independent Predictor of Residual Platelet Reactivity in Patients Undergoing Elective Percutaneous Coronary Intervention? *Circulation* 2010; 122: A20979.
23. Muller O, Delrue L, Hamilos M, Vercauteren S, Ntalianis A, Trana C, **Mangiaccapra F**, Dierickx K, De Bruyne B, Wijns W, Behfar A, Barbato E, Terzic A, Vanderheyden M, Bartunek J. Angiogenic and Inflammatory Whole Blood Transcriptional Fingerprint at the Site of Coronary Occlusion in Acute Myocardial Infarction. *Circulation* 2010; 122: A20805.
24. Ntalianis A, El Aidi F, Puymirat E, Conte M, **Mangiaccapra F**, Peace A, Sharif F, Muller O, Vanderheyden M, Barbato E, Wijns W, Bartunek J. Clinical Outcome After Revascularization With Primary PCI in Elderly Presenting Acute ST-elevation Myocardial Infarction: A Single Center Registry. *Circulation* 2010; 122: A20694.
25. Ntalianis A, Peace A, Puymirat E, **Mangiaccapra F**, Conte M, Mc Cann C, Eisenberger M, Hamilos M, Muller O, Barbato E, De Bruyne B, Wijns W. Fractional Flow Reserve versus Coronary Pressure Reserve To Predict Major Cardiovascular Events In Patients With Equivocal Left Coronary Artery Stenosis. *Circulation* 2010; 122: A18216.
26. Ntalianis A, Bodea O, Delrue L, Trana C, Dierickx K, Heyndrickx B, Muller O, **Mangiaccapra F**, Barbato E, Vanderheyden M, Bartunek J. Renin-Angiotensin System Genetic Polymorphisms Associate with Left Ventricular Remodeling and Clinical Outcome in Patients with Severe Pressure Overload Cardiomyopathy. *Circulation* 2010; 122: A20666.
27. Ntalianis A, Sels JW, Davidavicius G, Tanaka N, Muller O, Trana C, **Mangiaccapra F**, Hamilos M, Wijns W, Pijls NH, De Bruyne B. Fractional Flow Reserve in Acute Coronary Syndromes; Factors That Might Determine the Accurate Evaluation of the Non-Culprits. *Circulation*, 2010; 122: A20613.
28. Muller O, Ntalianis O, Delrue L, **Mangiaccapra F**, Trana C, Peace A, Auer R, Hamilos M, Valentin E, Wijns W, De Bruyne B, Vanderheyden M, Barbato E, Bartunek J. Serum Spla2 Activity, Spla2-IIa Mass and Oxldl Levels Are Related to the Significance of the Coronary Stenosis in Patients With Stable Coronary Artery Disease. *Circulation* 2010; 122: A21315.
29. **Mangiaccapra F**, Trana C, Sarno G, Davidavicius G, Protasiewicz M, Muller O, Ntalianis A, Misonis N, Van Vlem B, Heyndrickx GR, De Bruyne B. Translesional Pressure Gradients to Predict the Blood Pressure Response after Renal Artery Stenting in Patients with Renovascular Hypertension. *Circulation* 2010; 122: A15811.
30. Nam CW, **Mangiaccapra F**, Entjes R, Chung IS, Tonino PAL, De Bruyne B, Pijls NHJ, Fearon WF. The fractional flow reserve-guided syntax score for risk assessment in multi-vessel coronary artery disease. *J Am Coll Cardiol* 2011; 57: E1090
31. Peace A, Bailleul E, **Mangiaccapra F**, Delrue L, Conte M, Puymirat E, Fraeyman

- A, Meeus P, Bartunek J, Barbato E. Platelet aggregation in stable angina patients treated with aspirin and clopidogrel is modulated by a 6.3 / 6.7 kb polymorphism of the platelet  $\alpha_2A$ -adrenergic receptor. *Eurointervention* 2011, 7 Supplement M: A357.
32. **Mangiaccapra F**, Peace A, Di Serafino L, Ntarladimas I, Wijns W, Barbato E. Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel. *Eurointervention* 2011, 7 Supplement M: A334.
33. Puymirat E, **Mangiaccapra F**, Peace A, Sharif F, Conte M, Bartunek J, Vanderheyden M, Wijns W, De Bruyne B, Barbato E. Five-year clinical outcome in patients with small vessel disease treated with drug-eluting vs. bare metal stenting. *Eurointervention* 2011, 7 Supplement M: A289.
34. **Mangiaccapra F**, Conte M, Tu S, Peace A, Di Serafino L, Ntarladimas I, Barbato E, De Bruyne B, Reiber J, Wijns W. Performance of three-dimensional vs. two-dimensional quantitative coronary angiography in discriminating functionally significant coronary stenoses according to fractional flow reserve. *Eurointervention* 2011, 7 Supplement M: A275.
35. Peace A, Feys H, **Mangiaccapra F**, Conte M, Muller O, Ntalianis A, Puymirat E, Delrue L, Bartunek J, Vanhoorelbeke K, Barbato E. ADAMTS13 antigen levels are associated with increasing atherosclerotic burden in patients with stable coronary artery disease. *Eurointervention* 2011, 7 Supplement M: A23.
36. Campanale C, Nusca A, Contuzzi R, Patti G, D'Ambrosio A, **Mangiaccapra F**, Di Sciascio G. Preliminary results from a randomised trial on the role of Glucose-Insulin-Potassium and N-Acetyl-Cysteine for prevention of contrast induced nephropathy in high -risk patients undergoing PCI. *Eurointervention* 2011, 7 Supplement M: A16.
37. **Mangiaccapra F**, Puymirat E, Peace A, Conte M, Ntarladimas I, Di Serafino L, Wijns W, Heyndrickx G, de Bruyne B, Barbato E. Clinical benefit from drug-eluting vs. bare metal stents after rotational atherectomy for the treatment of calcified coronary lesions: results from a single-centre registry. *Eurointervention* 2011, 7 Supplement M: A254.
38. **Mangiaccapra F**, Melikian N, de Bruyne B, Peace A, Di Serafino L, Ntarladimas I, Bartunek J, Heyndrickx G, Wijns W, Barbato E. Cholesterol levels predict the presence of coronary microvascular dysfunction. *Eurointervention* 2011, 7 Supplement M: A178.
39. **Mangiaccapra F**, Peace A, Conte M, Ntarladimas I, Di Serafino L, Bailleul E, de Bruyne B, Bartunek J, Wijns W, Barbato E. Peri-procedural variations of platelet function in patients undergoing PCI. *Eurointervention* 2011, 7 Supplement M: A356.
40. Di Serafino L, **Mangiaccapra F**, Peace A, Bartunek J, Wijns W, De Bruyne B, Heyndrickx G, Barbato E. Long-Term Clinical Outcome in Patients with Angiographically Intermediate Lesion of the Coronary Artery By-Pass Graft Deferred on the Basis of Fractional Flow Reserve Measurement. *Circulation* 2011; 124: A12106.



41. Fournier S, Eeckhout E, **Mangiaccapra F**, Trana C, Lauriers N, Beggah A, Monney P, Vogt P, Muller O. Circadian Variations Of Ischemic Burden Among Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Circulation* 2011; 124: A14858.
42. Barbato E, Sciarretta S, Bartunek J, **Mangiaccapra F**, Lambrechts D, Sinnaeve P, Van De Werf F, Fox KAA, Volpe M, Rubattu SA. Influence of rs5065 atrial natriuretic peptide gene variant on Coronary Artery Disease. *Eur Heart J* 2012;33 (suppl 1).
43. Pyxaras SA, **Mangiaccapra F**, Di Serafino L, Toth G, De Vroey F, Perkan A, De Bruyne B, Salvi A, Sinagra G, Barbato E. Synergistic effect of thrombus aspiration and glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention. *Eur Heart J* 2012;33 (suppl 1).
44. **Mangiaccapra F**, Peace AJ, Barbato E, Patti G, Gatto L, De Bruyne B, Di Sciascio G. Optimal thresholds for on-treatment platelet reactivity to predict clinical events after percutaneous coronary intervention are different in patients with and without diabetes mellitus. *Eur Heart J* 2012;33 (suppl 1).
45. Ricottini E, Patti G, **Mangiaccapra F**, Cannatà A, Cavallari I, Vizzi V, D'Ambrosio A, Mega S, Dicuonzo G, Di Sciascio G. Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing Percutaneous Coronary Intervention. *Eur Heart J* 2012;33 (suppl 1).
46. **Mangiaccapra F**, Peace AJ, Di Serafino L, Pyxaras S, Bartunek J, Wyffels E, Heyndrickx GH, Wijns W, De Bruyne B, Barbato E. Intracoronary enalaprilat to reduce microvascular damage occurring during elective percutaneous coronary intervention trial (Promicro trial): a randomized double-blind controlled study. *Eur Heart J* 2012;33 (suppl 1).
47. **Mangiaccapra F**, Ricottini E, Barbato E, Patti G, Vizzi V, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G. Incremental value of platelet reactivity over a risk score of clinical and procedural variables in predicting bleeding events after percutaneous coronary intervention. *J Am Coll Cardiol* 2012; 69: B17.
48. **Mangiaccapra F**, Ricottini E, Barbato E, Patti G, Vizzi V, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G. Impact of chronic kidney disease on platelet reactivity and clinical outcomes of patients undergoing percutaneous coronary intervention. *J Am Coll Cardiol* 2012; 69: B42.
49. Ricottini E, Patti G, Vizzi V, Pasceri V, **Mangiaccapra F**, Colonna G, Montinaro A, Cavallari I, D'Ambrosio A, Barbato E, Wijns W, Di Sciascio G. Clopidogrel Reloading In Patients With Acute Coronary Syndrome Undergoing Pci On Chronic Clopidogrel Therapy: Results Of The Armyda-8 Reload-Acs (Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty) Randomized Trial. *J Am Coll Cardiol* 2012; 61: E1924.
50. **Mangiaccapra F**, Demartini C, Barbato E, Ricottini E, Patti G, Vizzi V, D'Ambrosio A, De Bruyne B, Wijns W, Di Sciascio G. A new prognostic risk score including platelet reactivity for bleeding after percutaneous coronary

intervention via the femoral approach. *Eur Heart J* 2013;34 (suppl 1).

51. **Mangiacapra F**, Demartini C, Ntalianis A, Muller O, Delrue L, Dierickx K, Wijns W, De Bruyne B, Bartunek J, Barbato E. Asymmetric dimethylarginine predicts extent and functional significance of coronary atherosclerosis. *Eur Heart J* 2013;34 (suppl 1).
52. Pyxaras SA, Sinagra G, **Mangiacapra F**, Perkan A, Santangelo S, Salvi A, Toth G, De Bruyne B, Wijns W, Barbato E. Contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention without acute left ventricular ejection fraction impairment. *Eur Heart J* 2013;34 (suppl 1).
53. Toth G, Hamilos M, Pyxaras S, De Vroey F, **Mangiacapra F**, Di Serafino L, Muller O, Barbato E, Wijns W, De Bruyne B. Coronary angiography for defining coronary disease? A comparison with fractional flow reserve in a large, non-selected population. *Eur Heart J* 2013;34 (suppl 1).
54. **Mangiacapra F**, Barbato E, Ricottini E, Patti G, Vizzi V, D'Ambrosio A, De Bruyne B, Di Sciascio G. A new prognostic risk score including platelet reactivity for bleeding after percutaneous coronary intervention via the femoral approach. *J Am Coll Cardiol* 2013; 62: B96.
55. Fournier S, Puricel S, Morawiec B, Eeckhout E, **Mangiacapra F**, Trana C, Tapoonnier M, Iglesias JF, Michiels V, Stauffer JC, Beggah A, Monney P, Gobet S, Vogt P, Cook S, Muller O. Relationship Between Time of Day and Periprocedural Myocardial Infarction After Elective Angioplasty. *Circulation* 2013; 128:A9810.
56. Cavallari I, **Mangiacapra F**, Ricottini E, Patti G, D'ambrosio A, Melfi R, Nusca A, Miglionico M, Gallo P, Di Sciascio G. High platelet reactivity and periprocedural myocardial infarction: a significant correlation beyond definitions. *Eur Heart J* 2014;35 (suppl 1).
57. **Mangiacapra F**, Pellicano M, Di Serafino L, Bressi E, Peace A, Di Gioia G, Bartunek J, Wijns W, De Bruyne B, Barbato E. Effects of Prasugrel Versus Clopidogrel on Coronary Microvascular Function in Patients Undergoing Elective Percutaneous Coronary Intervention: a randomized double-blind study. *Eur Heart J* 2015;36 (suppl 1).
58. **Mangiacapra F**, Colaiori I, Ricottini R, Balducci F, Creta A, Scordino S, Demartini C, Di Sciascio G. Heart rate reduction by ivabradine for improvement of endothelial function in patients with coronary artery disease: the randomized open-label RIVENDEL study. *Eur Heart J* 2015;36 (suppl 1).

**Author of 80+ abstracts presented at Italian Cardiology Meetings.**

## **ACADEMIC METRICS**

Number of articles: 62 – normalized (2016): 77.5

Number of citations: 1065 – normalized (2016): 133.1

h-index: 17 – contemporary h-index (2016): 16

Impact factor (2014): 302.459

## **DISSERTATIONS**

1. *“Pharmacological Protection With Optimal Doses of Clopidogrel Before Percutaneous Coronary Intervention Attenuates P-Selectin Expression: Results From The ARMYDA-SELECT Substudy”* (Advisor: Prof. Germano Di Sciascio; Co-Advisor: Dr. Giuseppe Patti). M.D. Graduation Thesis. **Campus Bio-Medico University of Rome, July 2005.**
2. *“Role of Vascular Atherosclerosis in Platelet Response to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention”* (Advisor: Prof. Germano Di Sciascio; Co-Advisor: Dr. Emanuele Barbato). Cardiology Board Graduation Thesis. **Campus Bio-Medico University of Rome, November 2009.**
3. *“Role of platelet reactivity in patients undergoing percutaneous coronary intervention”* (Promoters: Prof. Jozef Bartunek, Prof. Frans van de Vosse; Co-Promotor: Dr. Emanuele Barbato). Ph.D. Graduation Thesis. **Eindhoven University of Technology, October 2012.**

## **ACADEMIC ACTIVITY**


- Personal tutor for medical students at Campus Bio-Medico University of Rome (2007 - present)
- Clinical tutor for medical students at Campus Bio-Medico University of Rome (2011 – present)
- Lecturer for medical students at Campus Bio-Medico University of Rome (2012 – present)
- Dissertation co-advisor for M.D. graduations:
  - *“Valore predittivo della funzione endoteliale periferica sulla presenza ed estensione di aterosclerosi coronarica”* (Candidate: Maria Raffaella Aicale; Advisor: Prof. G Di Sciascio). **Campus Bio-Medico University of Rome, July 2013.**
  - *“Confronto degli effetti di clopidogrel ad alte dosi e ticagrelor sulla reattività piastrinica e sulla funzione endoteliale in pazienti affetti da diabete mellito e malattia coronarica: risultati preliminari dello studio prospettico randomizzato CLOTILDIA”* (Candidate: Aureliano Ruggio;

Advisor: Prof. G Di Sciascio). **Campus Bio-Medico University of Rome, October 2013.**

- *“Valutazione combinata di funzione endoteliale periferica e spessore medio-intimale carotideo per la predizione della malattia coronarica: uno studio prospettico”* (Candidate: Mario Diplomatico; Advisor: Prof. G Di Sciascio). **Campus Bio-Medico University of Rome, July 2014.**
- *“Effetti di pradugrel versus clopidogrel sulla funzione microvascolare miocardica in pazienti sottoposti ad angioplastica coronarica elettiva: risultati preliminari dello studio ENDOPLATE”* (Candidate: Edoardo Bressi; Advisor: Prof. G Di Sciascio). **Campus Bio-Medico University of Rome, July 2014.**
- *“Effetti dell’ivabradina sulla funzione endoteliale in pazienti sottoposti ad angioplastica coronarica: risultati preliminari dello studio prospettico randomizzato RIVENDEL”* (Candidate: Francesco Balducci; Advisor: Prof. G Di Sciascio). **Campus Bio-Medico University of Rome, July 2014.**
- *“Terapia antiaggregante piastrinica di mantenimento con clopidogrel versus ticagrelor in pazienti affetti da diabete mellito e malattia coronarica: studio prospettico randomizzato CLOTILDIA”* (Candidate: Elena Panaioli; Advisor: Prof. G Di Sciascio). **Campus Bio-Medico University of Rome, July 2015.**

Rome, 26/V/2016

Fabio Mangiacapra, MD, PhD

A handwritten signature in black ink, reading "Fabio Mangiacapra". The signature is written in a cursive style and is centered below the printed name.